Healthcare Quarterly Reports and Event - Research Report on Hologic, Akorn, Synta, PDL, and Exact Sciences PR Newswire NEW YORK, November 4, 2013 NEW YORK, November 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Hologic Inc. (NASDAQ: HOLX), Akorn, Inc. (NASDAQ: AKRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), PDL BioPharma, Inc. (NASDAQ: PDLI), and Exact Sciences Corporation (NASDAQ: EXAS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Hologic Inc. Research Report On October 24, 2013, Hologic Inc. (Hologic) announced that it intends to release its Q4 FY 2014 results on Monday, November 11, 2013, after market close. Hologic reported that it will also host its Q4 FY 2014 conference call on the same day at 5:00 p.m. ET. The Company stated that the live webcast is accessible through its Investor Relations website, and the replay of the webcast will be available two hours after the completion of the call. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d132_HOLX] Akorn, Inc. Research Report On October 25, 2013, Akorn, Inc. (Akorn) announced its participation during the upcoming American Academy of Ophthalmology 2013 in New Orleans, LA. Akorn reported that it will be located at booth # 2838, from Saturday, November 16, 2013 to Tuesday, November 19, 2013. The Full Research Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/900c_AKRX] Synta Pharmaceuticals Corp. Research Report On October 29, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it will release its Q3 2013 results on Monday, November 4, 2013, before market open. Synta reported that the release will be followed by its Q3 2013 conference call at 10:00 a.m. ET. The Company further informed that the live webcast is accessible through its Investor Relations website, while the archived webcast will be available under the Webcasts and Events section on its Investor Relations website. The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/8ecc_SNTA] PDL BioPharma, Inc. Research Report On October 28, 2013, PDL BioPharma, Inc. (PDL) announced that it will release its Q3 2013 results on Wednesday, November 6, 2013, after market close. PDL reported that it will host its Q3 2013 conference call on the same day at 4:30 p.m. ET. The Company further informed that the live webcast and replay will be available under the Events and Presentations section on its website. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI] Exact Sciences Corporation Research Report On October 29, 2013, Exact Sciences Corporation (Exact Sciences) released its Q3 2013 results with total revenues of $1.0 million, which were flat as compared to Q3 2012. The Company posted a net loss of $11.2 million in Q3 2013, compared to a net loss of $13.0 million in Q3 2012. Exact Sciences reported diluted loss per share of $0.16 in Q3 2013, compared to diluted loss per share of $0.21 in Q3 2012. Kevin T. Conroy, President and CEO, Exact Sciences, said, "As Cologuard moves through the FDA approval process, we also are focused on commercial readiness and operational excellence." Conroy continued, "The combination of Cologuard and our service that will make it easy for physicians to order and patients to use our test is a powerful one. We believe that this combination will increase the colorectal cancer screening rate and positively impact patient health." The Full Research Report on Exact Sciences Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9c49_EXAS] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com/ SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
Healthcare Quarterly Reports and Event - Research Report on Hologic, Akorn, Synta, PDL, and Exact Sciences
Press spacebar to pause and continue. Press esc to stop.